Thus, BH3 mimetics, such as Navitoclax, Venetoclax, and MCL-1 inhibitors have been exploited for cancer therapy and have proven clinical activity in some leukemias and lymphomas [4,5]. This evidence concerns the gene MCL1 and cancer.